


Dicotyledon AB seeks capital for male sexual health remedy

Dicotyledon AB has discovered the libiguins, which are promising remedies for treatment of sexual disability in men, viz. impotence and premature ejaculation. The libiguins have a natural origin and were coined by the press as “super Viagra” due to their powerful and long-lasting effects, improving sexual ability in men.

Dicotyledon technology covers the libiguin series of compounds; pharmaceuticals and uses therefrom, and the synthesis of the libiguins allowing their production in commercial quantities. Dicotyledon patents were recently approved in Europe, USA and Australia and are pending elsewhere.

The estimated market for the libiguins is 40 billion SEK per year with potential to take shares from the Viagra/Cialis-markets, as well as covering new indication areas and areas where Viagra/Cialis are contraindicated.

Libiguins show remarkable potency and powerful actions on sexual performance in experimental animals. The effect is long-lasting, which makes planning unnecessary and



Effects of a synthetic libiguin on sexual behavior in male rats mating with female rats, 4 – 14 days following its administration. The panels show dose-dependent long-lasting increase of intromissions (left) and ejaculatory latency (right). The effects were assessed following a three-day daily initial administration at the indicated dosing. (n=10).

normalizes man-woman sexual relation. The synthetic libiguins are orally available allowing simple treatment with capsules or tablets. Available data indicate that the natural libiguin product markedly improves sexual ability in elderly men suffering from impotence (erectile dysfunction).

Developments are done through **Dicot AB**, a subsidiary owned by Dicotyledon and Uppsala University Holding. Capital is sought in Dicot for strengthening of IP-portfolio and recruitment of key person(s) to build further on existing and create new strategic alliances.

For further information contact:

Jarl Wikberg, MD, PhD
Dicotyledon AB
Tel +46-70-3 449 549
jarl.wikberg@dicotyledon.se

Lars Jonsson, MD, PhD
Uppsala University Holding AB
Tel. + 46-18-471 1842
lars.jonsson@holding.uu.se